Srinagar Magazine

SGLT2 inhibitors Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Lexicon Pharmaceuticals, Youngene Therapeutics, Novartis Pharma

 Breaking News
  • No posts were found

SGLT2 inhibitors Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Lexicon Pharmaceuticals, Youngene Therapeutics, Novartis Pharma

March 22
06:12 2023
SGLT2 inhibitors Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies - Lexicon Pharmaceuticals, Youngene Therapeutics, Novartis Pharma
The SGLT2 inhibitors market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage SGLT2 inhibitors pipeline products will significantly revolutionize the SGLT2 inhibitors market dynamics.

DelveInsight’s “SGLT2 inhibitors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the SGLT2 inhibitors, historical and forecasted epidemiology as well as the SGLT2 inhibitors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The SGLT2 inhibitors market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the SGLT2 inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; SGLT2 inhibitors Market Insights

 

SGLT2 inhibitors Overview

Sodium-glucose co-transporter-2 (SGLT2) inhibitors prevent glucose (sugar) from being reabsorbed. SGLT2 inhibitors help the kidneys eliminate sugar in the urine, lowering glucose levels. An SGLT2 inhibitor may be used along with diet and exercise to help lower blood sugar in people with Type 2 diabetes. It may be used alone or with other diabetes medications, depending on the patient.

 

Some of the key facts of the SGLT2 inhibitors Market Report: 

  • The SGLT2 inhibitors market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the Centers for Disease Control and Prevention (CDC) (2019), 28.7 million people of all ages—or 8.7% of the US population had diagnosed diabetes. 283,000 children and adolescents younger than age 20 years or 35 per 10,000 US youths had diagnosed diabetes
  • As per Aperican Liver Foundation (2022), NAFLD is the most common chronic liver condition in the United States. It’s estimated that about 25 percent of adults in the US have NAFLD. Of those with NAFLD, about 20 percent have NASH (5% of adults in the U.S.). Most people with NAFLD have simply fatty liver
  • According to International Diabetes Federation, 537 million people have diabetes in the world and more than 61 million people in the EUR Region; by 2045 this will rise to 69 million
  • According to the Centers for Disease Control and Prevention (CDC) (2021), more than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have chronic kidney disease (CKD)
  • Key SGLT2 inhibitors Companies: Lexicon Pharmaceuticals, Youngene Therapeutics, Novartis Pharmaceuticals, and others
  • Key SGLT2 inhibitors Therapies: LX4211 (sotagliflozin), YG1699, LIK066 (licogliflozin), and others

 

Get a Free sample for the SGLT2 inhibitors Market Report – 

https://www.delveinsight.com/sample-request/sglt2-inhibitors-market

 

Key benefits of the SGLT2 inhibitors Market report:

  1. SGLT2 inhibitors market report covers a descriptive overview and comprehensive insight of the SGLT2 inhibitors Epidemiology and SGLT2 inhibitors market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The SGLT2 inhibitors market report provides insights on the current and emerging therapies.
  3. SGLT2 inhibitors market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The SGLT2 inhibitors market report offers an edge that will help develop business strategies by understanding trends shaping and driving the SGLT2 inhibitors market.

 

Download the report to understand which factors are driving SGLT2 inhibitors epidemiology trends @ SGLT2 inhibitors Epidemiological Insights

 

SGLT2 inhibitors Market  

The dynamics of the SGLT2 inhibitors market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

 

SGLT2 inhibitors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

SGLT2 inhibitors Epidemiology Segmentation:

The SGLT2 inhibitors market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of SGLT2 inhibitors
  • Prevalent Cases of SGLT2 inhibitors by severity
  • Gender-specific Prevalence of SGLT2 inhibitors
  • Diagnosed Cases of Episodic and Chronic SGLT2 inhibitors

 

SGLT2 inhibitors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the SGLT2 inhibitors market or expected to get launched during the study period. The analysis covers SGLT2 inhibitors market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the SGLT2 inhibitors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major SGLT2 inhibitors market share @ SGLT2 inhibitors market forecast

 

SGLT2 inhibitors Therapies and Key Companies

  • LX4211 (sotagliflozin): Lexicon Pharmaceuticals
  • YG1699: Youngene Therapeutics
  • LIK066 (licogliflozin): Novartis Pharmaceuticals

 

SGLT2 inhibitors Market Strengths

  • Rising prevalence of Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Chronic Chronic Myocardial Infarction

 

Scope of the SGLT2 inhibitors Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key SGLT2 inhibitors Companies: Lexicon Pharmaceuticals, Youngene Therapeutics, Novartis Pharmaceuticals, and others
  • Key SGLT2 inhibitors Therapies: LX4211 (sotagliflozin), YG1699, LIK066 (licogliflozin), and others
  • SGLT2 inhibitors Therapeutic Assessment: SGLT2 inhibitors current marketed and SGLT2 inhibitors emerging therapies
  • SGLT2 inhibitors Market Dynamics: SGLT2 inhibitors market drivers and SGLT2 inhibitors market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • SGLT2 inhibitors Unmet Needs, KOL’s views, Analyst’s views, SGLT2 inhibitors Market Access and Reimbursement 

 

SGLT2 inhibitors Market Opportunities

  • Potentially large undiagnosed pool, expected to be realized with improvements in diagnosis and treatments
  • SGLT2 inhibitors improve cardiovascular outcomes, especially the risk of hospitalization for heart failure

Table of Contents 

1. SGLT2 inhibitors Market Report Introduction

2. Executive Summary for SGLT2 inhibitors

3. SWOT analysis of SGLT2 inhibitors

4. SGLT2 inhibitors Patient Share (%) Overview at a Glance

5. SGLT2 inhibitors Market Overview at a Glance

6. SGLT2 inhibitors Disease Background and Overview

7. SGLT2 inhibitors Epidemiology and Patient Population

8. Country-Specific Patient Population of SGLT2 inhibitors 

9. SGLT2 inhibitors Current Treatment and Medical Practices

10. SGLT2 inhibitors Unmet Needs

11. SGLT2 inhibitors Emerging Therapies

12. SGLT2 inhibitors Market Outlook

13. Country-Wise SGLT2 inhibitors Market Analysis (2019–2032)

14. SGLT2 inhibitors Market Access and Reimbursement of Therapies

15. SGLT2 inhibitors Market Drivers

16. SGLT2 inhibitors Market Barriers

17.  SGLT2 inhibitors Appendix

18. SGLT2 inhibitors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about SGLT2 inhibitors treatment, visit @ SGLT2 inhibitors Medications

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting